ReportGem ReportGem

U.S. COMPANY FILING

ELI LILLY & Co — Form 10-K filed 2026-02-12

Filed: 2026-02-12Company: ELI LILLY & CoTicker: LLYExchange: NYSEForm: 10-KReport period: 2025-12-31SEC accession: 0000059478-26-000013Event: earningsMateriality: 90

Filing text preview

Eli Lilly reported 2025 revenue of $65.18B, up 45% YoY, with net income of $20.64B (up 95%) and diluted EPS of $22.95. Growth was driven by Mounjaro and Zepbound, which together accounted for 56% of total revenue. Gross margin improved to 83.0%. R&D and SG&A expenses increased. The company continues heavy capital investment and faces risks from patent challenges, pricing pressure, and regulatory scrutiny.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2026-02-12Fed Rate Hike Expectations Cool, Weighing on Dollar; GBP/USD Continues to Rise2026-08-21US Inflation Cooling Lowers Rate Hike Expectations, Dollar Index Continues to Weaken2026-08-21ByteTree: US Covert QE Opens, Gold Bull Market Room Fully Unlocked2026-08-21Mogul predicts gold price could surge 10-fold to $30k-50k, warns of mine expropriation risk2026-08-21US Treasury's expanded long-term bond buyback expectations boost gold; gold may continue to strengthen2026-08-21How Long Can Iran's Oil Exports Survive $170M Daily Loss and UAE Supply Cut?2026-08-2110-Q2026-08-05 · 10-Q